Bone cancer is a type of cancer that originates from bone cells, and its treatment generally includes surgery, radiotherapy, and chemotherapy. However, in recent years, new approaches for treating bone cancer have been explored, and in this context, Platelet Rich Plasma (PRP) therapy has gained attention. PRP is a plasma rich in platelets and is known for its potential to accelerate tissue healing. This article examines the potential of PRP in the treatment of bone cancer under four headings: the biological effects of PRP, PRP and bone healing, the combination of PRP with chemotherapy and radiotherapy, and the clinical applications and future of PRP.
Biological Effects of PRP
PRP contains a high concentration of platelets and growth factors. These growth factors include platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF). These factors promote cell proliferation, angiogenesis, and tissue regeneration. PRP is known for its supportive effects on bone tissue healing, which may also be significant in the treatment of bone cancer.
PRP and Bone Healing
The ways in which PRP supports bone healing have been investigated in various studies. During the treatment of bone cancer, surgical interventions often lead to significant damage in bone tissue. PRP can accelerate the healing of this damaged tissue. Some studies have shown that PRP promotes the proliferation and differentiation of bone cells, accelerates the formation of bone matrix, and enhances angiogenesis. Due to these properties, PRP is thought to contribute to the postoperative healing process in bone cancer treatment.
Combination of PRP with Chemotherapy and Radiotherapy
Chemotherapy and radiotherapy are commonly used methods in the treatment of bone cancer. However, these treatments can lead to damage in bone tissue and adverse effects. PRP can be utilized to mitigate the negative effects of chemotherapy and radiotherapy. For instance, it has been shown that PRP may reduce bone marrow damage during chemotherapy and alleviate side effects such as mucositis caused by chemotherapy. Additionally, PRP is thought to enhance the healing of bone tissue after radiotherapy. In this context, the combined use of PRP with chemotherapy and radiotherapy may represent an important complementary therapy in the treatment of bone cancer.
Clinical Applications and Future of PRP
The clinical applications of PRP in the treatment of bone cancer are still in the early stages. However, given the potential benefits and biological effects of PRP, it is anticipated that it may be used more widely in the treatment of bone cancer in the future. Clinical studies should further investigate the efficacy and safety of PRP in bone cancer treatment. Additionally, the combination of PRP with other treatment methods and the optimal application protocols should be established. The potential of PRP in the treatment of bone cancer will be better understood through future research and may become more widely utilized in clinical practice.
Conclusion
PRP is a plasma rich in platelets and growth factors known for its potential to accelerate tissue healing. In the treatment of bone cancer, the biological effects of PRP, its role in supporting bone healing, its combination with chemotherapy and radiotherapy, and its clinical applications have been emphasized. The potential of PRP in the treatment of bone cancer will be better understood through future research and may become more commonly used in clinical applications. Therefore, PRP may serve as an important complementary therapy in the treatment of bone cancer.
References
Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dentistry. 2001;10(4):225-228.
Mishra A, Woodall J Jr, Vieira A. Treatment of tendon and muscle using platelet-rich plasma. Clinics in Sports Medicine. 2009;28(1):113-125.
Alsousou J, Thompson M, Hulley P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. Journal of Bone and Joint Surgery. British volume. 2009;91(8):987-996.